Stacey Sigmon's, Ph.D., study on the benefits of controlled Buprenorphine treatment for opioid wait listed adults, was featured in the National Institute on Drug Abuse's monthly digest, "NIDA Notes."

John Hughes, M.D., weighs in on the implications of possible marijuana legalization in Vermont. Read the full story, here.

T32 predoctoral fellow, Eli Klemperer, participated in the American Cancer Society's, "Great American Smoke Out", live stream Facebook event. To listen to his interview, visit UVMMC's Facebook page!

Andrea Villanti, Ph.D., has been awarded the SRNT 2018 Jarvik-Russell Early Career Award, honoring members early in their careers who have made extraordinary contributions to the field of nicotine and tobacco research.

John Hughes, M.D., has been appointed Deputy Editor of Nicotine and Tobacco Research, one of the few peer-reviewed journals devoted exclusively to the study of nicotine and tobacco.

VCBH Research News


VT Hub & Spoke Model Proves Effective against Opioid AddictionRawson Picture

An evaluation of the Vermont Hub & Spoke System of care, led by UVM/VCBH Research Professor, Richard Rawson, Ph.D., demonstrates success in combating Vermont's critical battle against opioid addiction. The report summary brief outlines the findings of the 2017 study to understand the impact of the model on those in treatment, and their families. The study shows a 96% decrease in opioid use after admittance into the Hub & Spoke treatment program, along with a 90% decrease in illegal activity among.

pm_special_issue_cover6e04e3e4b8896cc59be4ff0000359472Published: Preventive Medicine Fourth Special Issue, November 2017

The November 2017 Special Issue of Preventive Medicine (PM) is the fourth in a series that focuses on behavior change, health, and health disparities. Contributors to these Special Issues are selected from participants in the VCBH's Annual Conference on Behavior Change, Health, and Health Disparities. The topics covered are of critical importance to improving U.S. population health. Dr. Stephen Higgins, Guest Editor and Director of the Vermont Center on Behavior and Health, explains that, "behavior change represents an essential step in improving population health generally and curtailing health disparities more specifically." Please visit our Preventive Medicine web page to learn more about the Special Issue and to view the online publication.

Image of Kim Dittus

Former VCBH Project Director Receives 2017 Junior Researcher of the Year 

Recent VCBH COBRE Project Director, Kim Dittus, M.D., Ph.D., was honored by the Larner College of Medicine as the 2017 Faculty Practice- Junior Researcher of the Year. Kim was cited as having organized one of the first of its kind nationwide oncology rehabilitation program that provides a platform for her research program. She is the author of 42 peer-reviewed publications and it is particularly interested in the value of weight loss in breast cancer survivors and in the timing of exercise programs in relation to chemotherapy regimens.

Image of Sharon Walsh

Sharon Walsh, Ph.D., 2018 VCBH Conference Keynote Speaker

Sharon Walsh, Ph.D., Professor of Behavioral Science and Psychiatry, and Director of the Center on Drug and Alcohol Research at the University of Kentucky, has been announced as the 2018 VCBH Conference Keynote Speaker!

The 2018 VCBH Conference will take place October 11 & 12, at the Burlington Hilton Hotel, in Burlington, Vermont. More information will be made available on our 2018 Conference web page.

Success at the 5th Annual VCBH Conference on Tobacco Regulatory Science

The 5th Annual VCBH Conference, held October 5-6 in Burlington, Vermont, brought together leading tobacco researchers from universities and medical centers nationwide to share their knowledge on tobacco regulatory science. Keynote speaker, Mitch Zeller, J.D., gave an outstanding presentation outlining the FDA's new plan for nicotine regulation, which has the potential to reduce overall smoking prevalence and improve public health. To view this talk and all others, please click here

Image of Stacey Sigmon

Sigmon receives NIDA Grant to Continue Evaluation of Interim Buprenorphine Treatment

Stacey C. Sigmon, Ph.D., received a $3.7 million grant from the National Institute of Drug Abuse (NIDA) to continue the development and evaluation of a novel Interim Buprenorphine Treatment (IBT) that leverages pharmacotherapy, state-of-the-art technology and rigorous methodology to bridge existing delays in treatment access. "In an initial R34 randomized pilot study, we demonstrated reductions in illicit opioid use and risk behaviors among wait listed opioid abusers receiving IBT. This project will seek to replicate those highly promising initial results while simultaneously evaluating generality of our findings to additional rural settings outside of our single University of Vermont academic medical center."

Image of YIR cover

Click here to read the 2016-2017 VCBH Year in Review.